Literature DB >> 18544121

Transfusion-associated graft-versus-host disease.

D M Dwyre1, P V Holland.   

Abstract

Transfusion-associated graft-versus-host disease (TA-GvHD) is a rare complication of transfusion of cellular blood components producing a graft-versus-host clinical picture with concomitant bone marrow aplasia. The disease is fulminant and rapidly fatal in the majority of patients. TA-GvHD is caused by transfused blood-derived, alloreactive T lymphocytes that attack host tissue, including bone marrow with resultant bone marrow failure. Human leucocyte antigen similarity between the transfused lymphocytes and the host, often in conjunction with host immunosuppression, allows tolerance of the grafted lymphocytes to survive the host immunological response. Any blood component containing viable T lymphocytes can cause TA-GvHD, with fresher components more likely to have intact cells and, thus, able to cause disease. Treatment is generally not helpful, while prevention, usually via irradiation of blood components given to susceptible recipients, is the key to obviating TA-GvHD. Newer methods, such as pathogen inactivation, may play an important role in the future.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18544121     DOI: 10.1111/j.1423-0410.2008.01073.x

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  18 in total

Review 1.  Recommendations for transfusion therapy in neonatology.

Authors:  Gabriella Girelli; Stefano Antoncecchi; Anna Maria Casadei; Antonio Del Vecchio; Paola Isernia; Mario Motta; Daniela Regoli; Costantino Romagnoli; Gino Tripodi; Claudio Velati
Journal:  Blood Transfus       Date:  2015-07       Impact factor: 3.443

Review 2.  Transplantation immunology: solid organ and bone marrow.

Authors:  Javier Chinen; Rebecca H Buckley
Journal:  J Allergy Clin Immunol       Date:  2010-02       Impact factor: 10.793

3.  Impact of sex, MHC, and age of recipients on the therapeutic effect of transferred leukocytes from cancer-resistant SR/CR mice.

Authors:  John R Stehle; Michael J Blanks; Gregory Riedlinger; Jung W Kim-Shapiro; Anne M Sanders; Jonathan M Adams; Mark C Willingham; Zheng Cui
Journal:  BMC Cancer       Date:  2009-09-15       Impact factor: 4.430

4.  Transfusion associated graft versus host disease following whole blood transfusion from an unrelated donor in an immunocompetent patient.

Authors:  Ketan K Patel; Atul K Patel; Rajiv R Ranjan; Apurva P Shah
Journal:  Indian J Hematol Blood Transfus       Date:  2010-10-01       Impact factor: 0.900

Review 5.  Transfusion-associated microchimerism: the hybrid within.

Authors:  Evan M Bloch; Rachael P Jackman; Tzong-Hae Lee; Michael P Busch
Journal:  Transfus Med Rev       Date:  2012-10-24

6.  Transfusion-Associated Graft-Versus-Host Disease with a Non-fatal Course.

Authors:  Suruchi Gupta; Tushar Sehgal; Man Updesh Singh Sachdeva; Shano Naseem; Reena Das; Ritambhra Nada
Journal:  Indian J Hematol Blood Transfus       Date:  2016-04-12       Impact factor: 0.900

Review 7.  Concise review: acute graft-versus-host disease: immunobiology, prevention, and treatment.

Authors:  Anthony D Sung; Nelson J Chao
Journal:  Stem Cells Transl Med       Date:  2012-12-19       Impact factor: 6.940

Review 8.  Leukoreduction for the prevention of adverse reactions from allogeneic blood transfusion.

Authors:  Daniel Simancas-Racines; Dimelza Osorio; Arturo J Martí-Carvajal; Ingrid Arevalo-Rodriguez
Journal:  Cochrane Database Syst Rev       Date:  2015-12-03

9.  Recommendations on Selection and Processing of RBC Components for Pediatric Patients From the Pediatric Critical Care Transfusion and Anemia Expertise Initiative.

Authors:  Nicole D Zantek; Robert I Parker; Leo M van de Watering; Cassandra D Josephson; Scot T Bateman; Stacey L Valentine; Meghan Delaney
Journal:  Pediatr Crit Care Med       Date:  2018-09       Impact factor: 3.624

10.  Development of fludarabine formulations in the treatment of chronic lymphocytic leukemia.

Authors:  Ann Janssens; Marc Boogaerts; Gregor Verhoef
Journal:  Drug Des Devel Ther       Date:  2009-12-29       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.